Manipulating the human microbiome appears to be an effective approach for treating a range of inflammatory, metabolic, and neurodegenerative diseases, among them inflammatory bowel disease, diabetes, and Parkinson’s disease. Yet the promise of this approach has been hindered by significant barriers in drug development.
In this article published in STAT, we discuss how drug manufacturers must strategically coordinate development and commercialization for emerging microbiome-based therapies in order to succesfully address challenges associated with them.
